BIOMARIN INTERNATIONAL LIMITED

BioMarin International Limited is a global biotechnology company dedicated to translating genetic discoveries into transformative medicines for people living with rare, life-threatening conditions. Since its founding in 1997, BioMarin has built a portfolio of eight marketed products that address severe disorders such as achondroplasia, haemophilia A, and a range of inherited and lysosomal-storage diseases. The company's pipeline, spanning clinical and pre-clinical stages, reflects a relentless pursuit of bold science and a commitment to delivering new therapeutic options.

Recent strategic moves underscore BioMarin's leadership in rare-disease care. The announced acquisition of Amicus Therapeutics will broaden its reach into Fabry disease and Pompe disease, strengthening both its therapeutic offering and financial outlook. Across its operations, BioMarin places patients at the centre of its work, listening to community insights and collaborating on solutions that improve everyday care. Backed by a talented, multidisciplinary team, the organisation continues to drive innovative research while fostering a culture of collaboration and compassion for the patients it serves.